Walter Van Dyck

483 total citations
36 papers, 312 citations indexed

About

Walter Van Dyck is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health and Physiology. According to data from OpenAlex, Walter Van Dyck has authored 36 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 6 papers in Public Health, Environmental and Occupational Health and 6 papers in Physiology. Recurrent topics in Walter Van Dyck's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (12 papers) and Biomedical Ethics and Regulation (6 papers). Walter Van Dyck is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (12 papers) and Biomedical Ethics and Regulation (6 papers). Walter Van Dyck collaborates with scholars based in Belgium, Austria and Spain. Walter Van Dyck's co-authors include Stefan Stremersch, Isabelle Huys, Steven Simoens, Bart Leten, Nancy Van Damme, Dušan Popović, Peter M. Allen, Volker Lohweg, Massimo Riccaboni and Christian Eitzinger and has published in prestigious journals such as Journal of Marketing, Scientific Reports and International Journal of Environmental Research and Public Health.

In The Last Decade

Walter Van Dyck

34 papers receiving 291 citations

Peers

Walter Van Dyck

EE

SM

MTI

MARKE

PHARM

Stephen M. Sammut United States

Richard G. Hamermesh United States

David Bardey Colombia

Öner Tulum United States

Salvatore Pirri Italy

Ashley J. Stevens United States

Pradip K. Bhaumik India

William Kingston Ireland

Michael A. Carrier Netherlands

R. Johnston United States

Stephen M. Sammut United States

Walter Van Dyck

118 ×0.9

EE

32 ×0.5

SM

46 ×0.9

MTI

9 ×0.3

MARKE

15 ×0.5

PHARM

Citations per year, relative to Walter Van Dyck Walter Van Dyck (= 1×) peers Stephen M. Sammut

Countries citing papers authored by Walter Van Dyck

Since Specialization

Citations

This map shows the geographic impact of Walter Van Dyck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter Van Dyck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter Van Dyck more than expected).

Fields of papers citing papers by Walter Van Dyck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter Van Dyck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter Van Dyck. The network helps show where Walter Van Dyck may publish in the future.

Co-authorship network of co-authors of Walter Van Dyck

This figure shows the co-authorship network connecting the top 25 collaborators of Walter Van Dyck. A scholar is included among the top collaborators of Walter Van Dyck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter Van Dyck. Walter Van Dyck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Dyck, Walter Van, et al.. (2025). Advanced therapy medicinal products are coming of age: A pipeline analysis of the clinical trial landscape. Drug Discovery Today. 30(10). 104459–104459. 1 indexed citations

2.

Simoens, Steven, Walter Van Dyck, Rosanne Janssens, Liese Barbier, & Jeroen Luyten. (2025). Compulsory Licensing as an Instrument to Tackle High Medicine Prices: A Realist Review of Industrial and Health Consequences. Applied Health Economics and Health Policy. 23(4). 613–624. 1 indexed citations

3.

Dyck, Walter Van, et al.. (2025). Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews. Frontiers in Pharmacology. 15. 1397531–1397531.

4.

Mol, Peter G. M., Walter Van Dyck, Anja Schiel, et al.. (2024). Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy. Health Research Policy and Systems. 22(1). 74–74. 7 indexed citations

5.

Ruof, Jörg, Peter G. M. Mol, Walter Van Dyck, et al.. (2024). Evaluating progress towards implementation of the European HTA Regulation: Insights generated from the European Access Academy's multi-stakeholder survey. Health Policy and Technology. 13(5). 100930–100930. 4 indexed citations

6.

Leten, Bart, et al.. (2023). Does constructive feedback improve idea quality in idea contests? Exploring the role of hierarchy and feedback overlap. R and D Management. 53(3). 345–363. 6 indexed citations

7.

Zimmeren, Esther van, Timo Minssen, Walter Van Dyck, et al.. (2022). Compulsory licensing for expensive medicines. 1 indexed citations

8.

Zimmeren, Esther van, Timo Minssen, Walter Van Dyck, et al.. (2022). Compulsory licensing for expensive medicines. 1 indexed citations

9.

Riccaboni, Massimo, et al.. (2022). Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model. Health Policy. 126(6). 534–540. 6 indexed citations

10.

Dyck, Walter Van, et al.. (2021). SM2 The Consequences of Greater Net Price Transparency for Innovative Medicines in Europe: Insights from a Multi-Agent Simulation Model. Value in Health. 24. S241–S241. 1 indexed citations

11.

Hoxhaj, Ilda, Steven Simoens, Walter Van Dyck, et al.. (2020). A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies. International Journal of Environmental Research and Public Health. 17(21). 8001–8001. 7 indexed citations

12.

Simoens, Steven, et al.. (2020). Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries. Value in Health. 23(5). 606–615. 13 indexed citations

13.

Dyck, Walter Van, et al.. (2020). Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. Frontiers in Pharmacology. 11. 594446–594446. 38 indexed citations

14.

Waeytens, Anouk, et al.. (2020). Evaluation of precision medicine assessment reports of the Belgian healthcare payer to inform reimbursement decisions. International Journal of Technology Assessment in Health Care. 36(4). 410–417. 2 indexed citations

15.

Hoxhaj, Ilda, Steven Simoens, Walter Van Dyck, et al.. (2020). OP523 Towards A Health Technology Assessment Framework For Omics-Technologies: Preliminary Results Of The ExACT project.. International Journal of Technology Assessment in Health Care. 36(S1). 13–13. 1 indexed citations

16.

Dyck, Walter Van, et al.. (2019). Acting with foresight in times of budget austerity. 1 indexed citations

17.

Huys, Isabelle, et al.. (2019). Real-World Evidence Gathering in Oncology: The Need for a Biomedical Big Data Insight-Providing Federated Network. Frontiers in Medicine. 6. 43–43. 9 indexed citations

18.

Dyck, Walter Van, et al.. (2016). The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation. 3 indexed citations

19.

Leten, Bart & Walter Van Dyck. (2012). Corporate venturing: Strategies and success factors. RePEc: Research Papers in Economics. 57(4). 243–257. 13 indexed citations

20.

Dyck, Walter Van. (2012). Building and leveraging your ecosystem to spark innovation-based growth. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact